Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

Author(s): Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F


Background:Methotrexate is the most frequent choice of disease-modifying antirheumatic therapy for rheumatoid arthritis. Although results of studies have shown the efficacy of such drugs, including methotrexate, on rheumatoid arthritis morbidity measures, their effect on mortality in patients with the disease remains unknown. Our aim was to prospectively assess the effect on mortality of methotrexate in a cohort of patients with rheumatoid arthritis.

Methods:Our cohort included 1240 patients with rheumatoid arthritis seen at the Wichita Arthritis Center, an outpatient rheumatology facility. Patients' details were entered into a computerised database at the time of their first clinic visit. We also obtained and recorded demographic, clinical, laboratory, and self-reported data at each follow-up visit (average interval 3.5 months). We estimated the mortality hazard ratio of methotrexate with a marginal structural Cox proportional hazards model.

Findings:191 individuals died during follow-up. Patients who began treatment with methotrexate (n=588) had worse prognostic factors for mortality. After adjustment for this confounding by indication, the mortality hazard ratio for methotrexate use compared with no methotrexate use was 0.4 (95% CI 0.2-0.8). Other conventional disease-modifying antirheumatic drugs did not have a significant effect on mortality. The hazard ratio of methotrexate use for cardiovascular death was 0.3 (0.2-0.7), whereas that for non-cardiovascular deaths was 0.6 (0.2-1.2).

Interpretation:Our data indicate that methotrexate may provide a substantial survival benefit, largely by reducing cardiovascular mortality. This survival benefit of methotrexate would set a standard against which new disease-modifying antirheumatic drugs could be compared.

Similar Articles

Cardiovascular death in rheumatoid arthritis: a population-based study

Author(s): Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE

Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study

Author(s): Hakoda M, Oiwa H, Kasagi F, Masunari N, Yamada M, et al.

Cause of death in 81 autopsied patients with rheumatoid arthritis

Author(s): Suzuki A, Ohosone Y, Obana M, Mita S, Matsuoka Y, et al.

Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility

Author(s): Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW

[Cause of death in autopsied RA patients]

Author(s): Toyoshima H, Kusaba T, Yamaguchi M

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Author(s): Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al.

Death certificate and mortality in rheumatoid arthritis

Author(s): Laakso M, Isomäki H, Mutru O, Koota K

Natural history and outcome in systemic AA amyloidosis

Author(s): Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, et al.

The mortality of rheumatoid arthritis

Author(s): Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, et al.